Clinical Trial

Clinical Study of Safety and Efficacy of Universal PSMA CAR- T in Refractory CRPC

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a single-arm, single-center, open-label clinical trial designed to evaluate the clinical safety and tolerability of different doses of Prostate-Specific Membrane Antigen (PSMA)-Universal Chimeric Antigen Receptor (UCAR) T-lymphocytes (PSMA-UCAR T) for the treatment of patients with refractory castration-resistant prostate cancer (CRPC).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-03-25; most recent amendment 2026-07-22.
Status change: Recruiting → Active, Not Recruiting 2026-04-22
Status change: Not Yet Recruiting → Recruiting 2025-04-08
Trial Details
NCT Number NCT06895811
Lead Sponsor Shanghai Changzheng Hospital
Collaborators: Bioray Laboratories
Conditions Metastatic Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Enrollment 3 participants
Start Date 2025-03-27
Primary Completion 2026-07 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2026-07-23